# Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

> **NCT04331795** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 32 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04331795
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-04
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-06-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04331795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04331795, "Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04331795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*